Genmab A/S ADR (GMAB) Stock Price, Quote & News

Company Profile

Genmab A/S, a biotechnology company, develops antibody-based products and product candidates for the treatment of cancer and other diseases in Denmark. The company markets EPKINLY and TEPKINLY for adult patients with relapsed or refractory (R/R) diffuse large b-cell lymphoma (DLBCL), large B-cell lymphoma, and follicular lymphoma (FL); and Tivdak for adult patients with recurrent/metastatic cervical cancer with disease progression on or after chemotherapy. It is also developing Epcoritamab for R...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 70 20 27 28

Website: www.genmab.com

Address:

Carl Jacobsens Vej 30, Valby, Copenhagen, Denmark

FiveMinute Aug. 27 at 9:13 PM

🎯 $GMAB — Continuation setup, up to +10% to target ($37.51) BB_RANK 57/100 | Fundamentals 60/100 | +6.18% above EMA20 Detected 8/27, present 4 of last 5 sessions. Support: $31.59 | Resistance: $34.68 TP1: $35.80 (+5%) | TP2: $37.51 (+10%) Status: EN OBSERVATION Not financial advice.

0 · Reply

FiveMinute Aug. 26 at 9:12 PM

$GMAB 📈 Automated swing setup flagged tonight (8/26)! Appeared in 4 of the last 5 sessions.🔥 CONTINUATION setup• Ref Price: $33.75• Price +5.78% above EMA20 ($31.91)• RSI: 68.1 (neutral-high, strong momentum)• Volume: 3.09M (105% of avg • Moderate)• Scores: BB_RANK 56.5/100 | Fund. 60/100 | Tech. 55/100🎯 Key Levels to watch:• Targets: $35.44 (TP1) / $37.12 (TP2)• Resistance: $33.96• Support / Interest Zone: $31.59 – $32.33• Invalidation (SL): $32.06STATUS: EN OBSERVATION 👀 Healthy bullish alignment above key EMAs. Watch for a potential healthy retest of the EMA20 interest zone or a clean breakout past resistance.What's the play here, bulls? 🚀 #SwingTrading #TechnicalAnalysis #Biotech Not financial advice.

0 · Reply

JuggernautRaider Aug. 26 at 8:46 PM

$TNXP who cares about money when we have human brothers and sisters whose souls are burning in Hell right now? We can unleash them. How about Psalm 41? Who needs some healing? Click this link for some beautiful healing scripture 📕 🙏 💚 https://www.biblegateway.com/passage/?search=Psalm%2041&version=NIV $ALT $CCCC $GMAB why not?

0 · Reply

WallStJesus Aug. 25 at 7:25 PM

$GMAB

0 · Reply

FiveMinute Aug. 24 at 9:30 PM

$GMAB — Automated swing setup flagged tonight (8/24), appeared in 3 of the last 5 sessions. CONTINUATION setup, price +5.04% above EMA20. Fundamentals 60/100. Ref price: $33.02 Support: $31.59 | Resistance: $33.63 Invalidation: $31.37 Theoretical targets: $34.67 / $36.32 RSI: 68.4 (neutral-high) Status: EN OBSERVATION. Not financial advice.

0 · Reply

Quantumup Aug. 21 at 12:19 PM

Stifel reiterated $INBX Buy-$325 after it recently hosted a series of investor meetings w/ Mark Lappe (Founder, CEO) & Kelly Deck (EVP, CFO). $BNTX $GMAB BGNE SNY CMTX IMNM PRTA PHMMF DCOY Here's what Stifel said in its note to investors: https://x.com/Quantumup1/status/2090775723531219121?s=20

0 · Reply

Quantumup Aug. 21 at 11:34 AM

Citizens reiterated $BCAX Market Outperform-$31 after Bicara recently reported 2Q26 financial results. MRUS - $GMAB $JNJ LLY MRK BMY ANZ INCY EXEL PFE SMMT Citizens said -- With Bicara's pivotal trial advancing rapidly, initial mCRC data expected in 2H26, and a cash position of $497.3MM, we believe Bicara shares represent an attractive investment opportunity, with ~55% potential downside (bear case $11) and ~93% potential upside (bull case $47).

0 · Reply

FiveMinute Aug. 20 at 9:17 PM

$GMAB — Automated swing setup flagged tonight (8/20), 2 of the last 5 sessions. CONTINUATION setup, price +7.64% above EMA20. Fundamentals 60/100. Ref price: $33.41 Support: $31.59 | Resistance: $33.63 Invalidation: $31.74 Theoretical targets: $35.08 / $36.75 RSI: 73.2 (overbought) Status: EN OBSERVATION. Not financial advice.

0 · Reply

JuggernautRaider Aug. 20 at 8:20 PM

$IXHL hmm so much potential 😋 $CCCC $CGEM $GMAB also woah 😋 🍱 🍣

0 · Reply

FiveMinute Aug. 19 at 8:59 PM

$GMAB — Automated swing setup flagged tonight (8/19), new appearance. CONTINUATION setup, price +10.90% above EMA20. Fundamentals 60/100. Ref price: $34.11 Support: $31.59 | Resistance: $34.68 Invalidation: $32.40 Theoretical targets: $35.82 / $37.52 RSI: 81.0 (overbought) Status: EN OBSERVATION. Not financial advice.

0 · Reply

Market Cap	21.26B
Revenue (ttm)	3.72B
Net Income (ttm)	963.00M
EPS (ttm)	N/A
PE Ratio	24.28
Forward PE	28.93
Profit Margin	25.89%
Debt to Equity Ratio	0.86

Volume	1,514,300
Avg Vol	2,331,278
Day's Range	N/A - N/A
Shares Out	623.53M
Stochastic %K	31%
Beta	0.83
Analysts	Strong Sell
Price Target	$38.60